Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

Creative Bioarray stands at the forefront of providing the most comprehensive animal model services tailored for the methionine and choline deficient (MCD) diet-induced nonalcoholic fatty liver disease (NAFLD) model in mice. We can deliver robust results at highly competitive prices, ensuring that our clients can significantly accelerate their drug development processes. At Creative Bioarray, we are not just service providers; we are your partners in innovation, dedicated to propelling your research forward and bringing your discoveries to the market faster.

The MCD diet, which is commonly used in NAFLD animal studies, is characterized by a high sucrose content (40%) and a moderate amount of fat (10%). However, it lacks sufficient methionine and choline. Methionine is an essential amino acid that cannot be produced by the body and plays a crucial role in the synthesis of various compounds such as cysteine, lecithin, phosphatidylcholine, and others. Similarly, choline is an important component of cell and mitochondrial membranes and serves as a precursor for acetylcholine. The deficiency of these two components leads to impaired synthesis of phosphatidylcholine, resulting in reduced assembly and secretion of VLDL. Consequently, there is a decrease in triglyceride (TG) clearance, leading to the accumulation of lipids in the liver. This model also exhibits other pathological features, including impaired mitochondrial β-oxidation, increased oxidative stress from CYP2E1, and depletion of hepatic antioxidants. These factors contribute to the development of reactive oxygen species (ROS) and steatohepatitis.

Our Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

• Available Animal

Mouse

• Modeling Method

Animals are fed a MCD diet for 3-4 weeks to induce NAFLD.

Fig. 1 Modeling method for the MCD diet-induced NAFLD model.

• Endpoints

• Body weight
• Liver weight
• Survival rate
• Serum analysis: ALT, AST, TG, TC
• Histology analysis: H&E staining, Oil red O staining
• qPCR or Western blot
• Other customized endpoints

Example Data

Fig. 2 Liraglutide infusion does not quantitatively change hepatic lipid accumulation in MCD diet-fed mice. (A) Relative liver mass. (B) Circulating alanine aminotransferase (ALT) levels. (C) Circulating aspartate aminotransferase (AST) levels. (D) Circulating free fatty acid (FFA) levels. (E) Circulating total cholesterol levels. (F) Circulating triglyceride levels. (G) Haematoxylin and eosin (H&E) and Oil-red O staining of liver sections. (H) Quantification of lipids expressed as percent of area of liver sections stained with Oil red O. (I) Evaluation of the percent of hepatocyte containing micro- and macrosteatosis. (J) Pathological score with steatosis and activity. (K) Hepatic gene expression of lipids enzymes and transporters. (Somm et al. 2021)

Meanwhile, we also provide other NAFLD models that maybe you are interested in:

• High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

Quotation and Ordering

Creative Bioarray is a leading research partner that specializes in offering a wide range of rodent disease models and comprehensive services with expertise in the field. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.

References

1. Nevzorova, Y.A., et al. Animal models for liver disease–a practical approach for translational research. Journal of hepatology, 2020, 73(2): 423-440.
2. Somm, E., et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Translational research, 2021, 227: 75-88.

Explore Other Options

• Alloxan-Induced Type 1 Diabetes Model
• Animal Model of Hyperuricemia
• High Fat Diet-Induced Obesity Model
• Nonalcoholic Fatty Liver Disease Model
• Type 1 Diabetes Mellitus Model

• Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

For research use only. Not for any other purpose.